Background {#Sec1}
==========

Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality worldwide \[[@CR1]\]. In China, the incidence and mortality rate of CRC are ranked fourth and third of all malignant tumors, respectively, and the incidence rate of CRC is increasing year by year \[[@CR2]\]. Patients with CRC have an unfavorable prognosis; however, the prognosis of CRC is better when the disease is diagnosed in the early stages \[[@CR3]\]. Routine blood biomarkers are not powerful enough to aid diagnosis or predict prognosis in patients with CRC \[[@CR4]\]. Therefore, the development of novel diagnostic and prognostic biomarkers is crucial to reduce CRC-related deaths.

Recent advances in novel genetic and epigenetic biomarkers for the management of CRC have provided new research perspectives. Circular RNAs (circRNAs) are non-coding RNA molecules that lack a 5′-terminal cap and 3′-terminal poly A tail \[[@CR5]\]. CircRNAs are abundant in cells and tissues and their unique sequences endow them with special biological properties such as cytoplasmic microRNA sponges, attaching elements of RNA-binding proteins, or nuclear transcriptional regulators \[[@CR6], [@CR7]\]. The formation of a covalently closed continuous loop also makes circRNAs more stable than linear mRNAs \[[@CR8]\]. In recent years, circRNAs have been highlighted as novel biomarkers for the management of CRC \[[@CR9]--[@CR21]\], but the findings remain controversial. The present study summarizes the clinicopathologic, diagnostic, and prognostic significance of circRNAs in CRC patients via a meta-analysis.

Methods {#Sec2}
=======

Literature search {#Sec3}
-----------------

This study was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Checklist issued in 2009 \[[@CR22]\]. Online databases including PubMed, EMBASE, Web of Science, SCOPUS, and Chinese National Knowledge Infrastructure (CNKI) were searched for eligible studies that evaluated the diagnostic, prognostic or clinicopathologic significance of circRNA(s) in CRC. The following search terms were used with different combinations in different databases: "colorectal cancer", "colorectal carcinoma", "colorectal neoplasms", "carcinoma of colon", "circular RNA", "circRNA", "hsa circ", "clinicopathologic feature", "clinicopathological characteristics", "clinicopathological parameters", "diagnosis", "diagnoses", "sensitivity", "specificity", "area under the curve", "AUC", "ROC curve", "prognosis", "prognoses", "hazard ratio", "overall survival", "OS", and "HR". Patients with CRC were considered the "case group", whereas those with benign lesions or healthy individuals were considered the "control group or controls".

Study selection {#Sec4}
---------------

Inclusion criteria were: (1) original research reporting the diagnostic accuracy, or prognostic utility, or clinicopathologic association of single or parallel circRNAs in CRC; (2) the diagnosis of CRC was histopathologically confirmed; and (3) studies investigating the clinical utility of circRNA(s) in CRC, with sufficient data to plot the 2X2 table, or with available HR values and 95% confidence interval (CI), or available *P* values for clinicopathologic associations. Exclusion criteria were: (1) articles not published in English; (2) reviews, basic studies, comments, meta-analyses, letters or case reports; and (3) studies defined as low quality.

Data extraction {#Sec5}
---------------

Two authors each assessed the eligibility of all studies and extracted the data. The following data were extracted from each study: (1) baseline information including name of first author, date of publication, number of cases, control source, test matrix, method, reference gene, cut-off point, circRNA(s) type and expression status; (2) clinicopathologic information (as *P* values) regarding circRNA(s) expression and age, gender, cancer location, tumor diameter, differentiation, serosal invasion, lymphatic metastasis, distant metastasis, and TNM stage; (3) diagnostic data including sensitivity, specificity, area under the curve (AUC) value, or the true positive (TP), false positive (FP), false negative (FN), and true negative (TN) values; and (4) prognostic data including duration of follow-up, HR value and 95%CI for OS.

Quality assessment {#Sec6}
------------------

Study quality in relation to diagnosis was rated in accordance with the Quality Assessment for Studies of Diagnostic Accuracy II (QUADAS II) checklist, which comprises seven questions regarding patient selection, index tests, reference standards, flow, and timing \[[@CR23]\]. Risk of bias was rated as "no", "yes", or "unclear", and only an answer of "yes" received a score of 1, otherwise no score was awarded. Study quality in relation to prognosis was judged by the Newcastle-Ottawa Scale (NOS) \[[@CR24]\], wherein the risk regarding study selection, comparability, and outcome were assessed. A study was deemed to be of high quality when the QUADAS II score was ≥4 stars, and ≥ 6 stars for the NOS checklist \[[@CR25]\].

Statistical analysis {#Sec7}
--------------------

STATA software (version 12.0) was used to analyze the clinicopathologic and prognostic significance. Meta-Disc (version 1.4) was utilized to summarize the weighted diagnostic parameters including sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), overall diagnostic odds ratio (DOR) and AUC. Heterogeneity among studies was assessed by the *X*^2^ and inconsistency *I*^2^ (I-square) tests, and the cut-off point was set as *P* \< 0.05 in the *X*^2^ test or *I*^2^ \> 50%. Associations between circRNA expression and clinicopathologic parameters were determined using the *P* values combined with Fisher's test \[[@CR26]\]. HR and 95%CI were combined based on multivariate Cox hazard regression analysis, and the random effect model was chosen when significant heterogeneity was observed. Sensitivity and meta-regression tests were used to identify the underlying causes of heterogeneity \[[@CR25]\]. Publication bias was quantitatively judged by Deeks' funnel plot asymmetry test, Begg's and Egger's tests, and *P* \< 0.05 was considered statistically significant.

Results {#Sec8}
=======

Search results {#Sec9}
--------------

The study selection procedure is shown in Fig. [1](#Fig1){ref-type="fig"}. In the initial search, a total of 439 publications retrieved from PubMed, EMBASE, Web of Science, SCOPUS, and Chinese National Knowledge Infrastructure (CNKI) databases seemed to meet the inclusion criteria. Of these, 303 publications were identified as duplicates and were eliminated. After reading article titles and abstracts, 120 records were eliminated as no association between circRNA expression and CRC was described or the articles were reviews. In the full-text verification, 16 articles were excluded as the studies were out of topic or lacked sufficient data. Finally, 13 studies were included in the quantitative meta-analysis. Fig. 1Flow chart of the study search strategies

Study characteristics and study quality {#Sec10}
---------------------------------------

The included 13 studies comprised eight studies on clinicopathologic parameters \[[@CR9]--[@CR11], [@CR13], [@CR14], [@CR16], [@CR19], [@CR20]\], nine on diagnosis \[[@CR9]--[@CR14], [@CR16], [@CR19], [@CR20]\], and seven on prognosis \[[@CR10], [@CR12], [@CR14], [@CR15], [@CR17], [@CR18], [@CR21]\]. The baseline characteristics of all included studies are summarized in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. All 13 studies were carried out in Asia. A total of 1430 CRC cases were included, and the sample size ranged from 32 to 318. All CRC cases were diagnosed by histological and pathological examinations. The tissue samples were obtained prior to clinical treatment. circRNA expression level was determined using quantitative real-time polymerase chain reaction (qRT-PCR) or RNA sequencing, and the reference genes included *GAPDH* \[[@CR10]--[@CR18], [@CR20], [@CR21]\], *18S rRNA* \[[@CR9]\], and *U6* \[[@CR19]\]. Six types of circRNAs were recognized as tumor promoters \[[@CR12], [@CR15], [@CR16], [@CR18], [@CR19], [@CR21]\], and seven were tumor suppressors \[[@CR9]--[@CR11], [@CR13], [@CR14], [@CR17], [@CR20]\]. For survival analysis, the follow-up period was available in two studies, and three articles contained data on HR and 95% CI, whereas HR values in the remaining four articles were unclear and were calculated indirectly. Table 1Main characteristics of the meta-analysis for diagnostic performance and clinicopathologic association of circRNAs in CRCStudyLocalePatient numberControl numberControl typeSample TypeCircRNA signatureExpression status/Biological functionMethodCut-Off ValueReference geneAUCAssessed clinicopathologic associationWang J 2018 \[[@CR9]\]Chinese102102Adjacent noncancerous tissuesTissue*hsa_circ_0000567*Down-regulated/ Tumor suppressorqRT-PCR/2 − ΔΔCt0.4714*18S rRNA, GAPDH*0.8653YesWang F 2018 \[[@CR10]\]Chinese4646Pair-matched adjacent normal tissuesTissue*hsa_circ_0014717*Down-regulated/ Tumor suppressorqRT-PCR/2 − ΔΔCt/*GAPDH*0.683YesWang X 2015 \[[@CR11]\]Chinese6262Adjacent normal mucosaTissue*hsa_circ_001988*Down-regulated/ Tumor suppressorqRT-PCR/ΔCt6.04*GAPDH*0.788YesHsiao KY 2017 \[[@CR12]\]13176Paired noncancerous counterpartsTissue*circCCDC66*Up-regulated/ Tumor promotorRNA sequencing/*GAPDH*0.88YesZhang P 2017 \[[@CR13]\]Chinese170170Normal colorectal tissue samplesTissue*hsa_circRNA_104700*Down-regulated/ Tumor suppressorqRT-PCR/Ct10.753*GAPDH*0.699Yes*hsa_circRNA_103809*Down-regulated/ Tumor suppressorqRT-PCR/Ct13.9*GAPDH*0.616YesLi J 2018 \[[@CR14]\]Chinese101101Paired noncancerous counterpartsTissue*hsa_circ_0000711*Down-regulated/ Tumor suppressorqRT-PCR/ΔCtΔCt: 3.37*GAPDH*0.81YesJi WX 2018 \[[@CR16]\]Chinese6464Paired noncancerous counterpartsTissue*hsa_circ_0001649*Up-regulated/ Tumor promotorqRT-PCR0.278*GAPDH*0.857YesLi XN 2019 \[[@CR19]\]Chinese6060Adjacent normal mucosa tissuesPlasma*circVAPA*Up-regulated/ Tumor promotorqRT-PCR/2 − ΔΔCtMedian expression level of circVAPA*U6*0.724YesZhuo F 2017 \[[@CR20]\]Chinese122122Paired noncancerous counterpartsPlasma*circRNA0003906*Down-regulated/ Tumor suppressorqRT-PCR/2 − ΔΔCt/*GAPDH*0.818Yes*AUC* area under the curve, *GAPDH* reduced glyceraldehyde-phosphate dehydrogenase, *qRT-PCR* quantitative reverse transcription-polymerase chain reaction Table 2Mian characteristics of the meta-analysis for prognosis and clinicopathologic association of circRNAs in CRCStudyLocaleCase sizeTNM Stage (I, II, III, IV)Sample TypeCircRNA signatureExpression status/ Biological functionSurvival indicatorFollow-up timeHR & 95% CI ExtractionAssessed clinicopathologic associationHighLowWang F 2018 \[[@CR10]\]China2323I + II: 17, III + IV: 29Tissue*hsa_circ_0014717*Down-regulated/ Tumor suppressorOS1 to 3 month intervalsIndirectlyYesHsiao KY 2017 \[[@CR12]\]ChinaTotal: 131UnclearTissue*circCCDC66*Up-regulated/ Tumor promotorOSUnclearIndirectlyYesLi J 2018 \[[@CR14]\]China505121, 32, 40, 8Tissue*hsa_circ_0000711*Down-regulated/ Tumor suppressorOSMedain:39 monthDirectlyYesZeng K 2018 \[[@CR15]\]China8989I + II: 121, III + IV: 57Tissue*circHIPK3*Up-regulated/ Tumor promotorOSUnclearDirectlyNoYuan Y 2018 \[[@CR17]\]China1517UnclearTissue*circ_0026344*Down-regulated/ Tumor suppressorOSUnclearIndirectlyNoFang G 2018 \[[@CR18]\]China2420UnclearTissue*circRNA_100290*Up-regulated/ Tumor promotorOSUnclearIndirectlyNoWeng W 2017 \[[@CR21]\]China767719, 84, 47, 3Tissue*ciRS-7*Up-regulated/ Tumor promotorOSUnclearDirectlyNo897626, 52, 49, 38Tissue*ciRS-7*Up-regulated/ Tumor promotorOSUnclearDirectlyNo*OS* overall survival, *HR* hazard ratio

Study bias and quality assessed by QUADAS II and NOS checklists are shown in Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. The rating scores of all eligible studies for diagnosis ranged from 4 to 6, and for prognosis ranged from 6 to 8, indicating high methodological quality in all included studies. Table 3Study quality of the diagnostic studies, as judged by the QUADAS II checklistStudyRisk of biasConcerns regarding applicabilityTotal starsPatient selectionIndex testReference standardFlow and timingPatient selectionIndex testReference standardWang J 2018 \[[@CR9]\]LowUnclearLowLowUnclearLowLow5Wang F 2018 \[[@CR10]\]LowUnclearLowUnclearUnclearLowLow4Wang X 2015 \[[@CR11]\]LowUnclearLowLowUnclearLowLow5Hsiao KY 2017 \[[@CR12]\]LowUnclearLowUnclearUnclearLowLow4Zhang P 2017 \[[@CR13]\]LowUnclearLowUnclearUnclearLowLow4Li J 2018 \[[@CR14]\]LowUnclearLowUnclearUnclearLowLow4Ji WX 2018 \[[@CR16]\]LowUnclearLowUnclearUnclearLowLow4Li XN 2019 \[[@CR19]\]LowLowLowLowUnclearLowLow6Zhuo F 2017 \[[@CR20]\]LowLowLowLowUnclearLowLow6*QUADAS* Quality Assessment for Studies of Diagnostic Accuracy Table 4Study quality and bias in the retrospective cohort studies judged by the Newcastle-Ottawa Scale (NOS) checklistStudyTotal starCohort selectionComparabilityOutcome ascertainmentRepresentativeness of the Exposed CohortSelection of the Non-Exposed CohortAscertainment of ExposureDemonstration that Outcome of Interest Was Not Present at Start of StudyComparability of Cases and Controls on the Basis of the Design or AnalysisAssessment of OutcomeWas Follow-Up Long Enough for Outcomes to OccurAdequacy of Follow Up of CohortsWang F 2018 \[[@CR10]\]811111111Hsiao KY 2017 \[[@CR12]\]611111100Li J 2018 \[[@CR14]\]811111111Zeng K 2018 \[[@CR15]\]611111100Yuan Y 2018 \[[@CR17]\]611111100Fang G 2018 \[[@CR18]\]611111100Weng W 2017 \[[@CR21]\]611111100

Meta-analysis of clinical parameters {#Sec11}
------------------------------------

The association between circRNAs and clinicopathologic features in patients with CRC is shown in Table [5](#Tab5){ref-type="table"}. Altered expression of circRNAs was markedly associated with poor clinicopathologic parameters (tumor diameter: pooled *P* = 0.0350; differentiation: pooled *P* = 0.0038; lymphatic metastasis: pooled *P* = 0.0119; distant metastasis: pooled *P* \< 0.0001; TNM stage: pooled *P* = 0.0002; depth of invasion: pooled *P* = 0.0016). In contrast, no significant correlations were observed for age (pooled *P* = 0.3141), gender (pooled *P* = 0.5696), tumor location (pooled *P* = 0.8627), as well as levels of carcinoembryonic antigen (CEA) (pooled *P* = 0.2047), and carbohydrate antigen (CA) 19--9 (pooled *P* = 0.7954). Table 5Associations between circRNAs expression and clinicopathological features in CRC analyzed by Fisher's testClinicopathological factorsCombined\
*P* value*X*^2^ valueEnrolled StudiesAge0.31413520.337649Gender0.56961616.328749Cancer location0.862753.9371344Diameter0.03503222.229026Differentiation0.00383238.035429Lymphatic metastasis0.01194422.691545Distal metastasis1.04E-0537.235584TNM stage0.00022933.444285CEA level0.2047538.4838653CA19--9 level0.7954344.6383854Depth of invasion0.00162724.883873

Diagnostic performance {#Sec12}
----------------------

The weighted diagnostic parameters of circRNAs in distinguishing CRC from non-tumor controls were as follows: sensitivity of 0.77 (95%CI: 0.70--0.82), specificity of 0.81 (95%CI 0.73--0.86), PLR of 4.00 (95%CI 2.80--5.60), NLR of 0.29 (95%CI 0.22--0.38), DOR of 14.0 (95%CI 8.0--24.0), and AUC of 0.86. Forest plots of the pooled sensitivity, specificity, DOR and summary receiver operating characteristic (ROC) curve of circRNAs in diagnosing CRC are shown in Fig. [2](#Fig2){ref-type="fig"}. Fig. 2**a** Forest plots of the combined sensitivity, (**b**) specificity, (**c**) DOR, and (**d**) AUC for circRNAs expression in diagnosing CRC

Stratified analysis showed that the performance of up-regulated circRNAs (function as tumor promoters) for CRC detection was significantly superior to that of down-regulated circRNAs (function as tumor suppressors) (AUC: 0.86 vs. 0.75; DOR: 10.63 vs. 6.55). When analyzed based on test matrix, these results showed that tissue-based circRNA testing achieved higher diagnostic efficacy than plasma-based analysis (AUC: 0.79 vs. 0.50; DOR: 7.68 vs. 7.13).

Overall survival {#Sec13}
----------------

Survival analysis showed that oncogenic circRNAs predict worse prognosis in terms of OS in patients with CRC (HR = 2.66, 95%CI: 2.03--3.50, *P* = 0.000; *Chi*^2^ = 4.34, *P* = 0.740, *I*^2^ = 0.0%) (Fig. [3](#Fig3){ref-type="fig"}). We identified one outlier study in the combined effect of decreased circRNAs by sensitivity analysis (Fig. [4](#Fig4){ref-type="fig"}), and the outlier data were eliminated. The weighted effect showed that decreased circRNAs expression (function as tumor suppressors) in patients with CRC was associated with favorable OS (weighted HR = 0.30, 95%CI: 0.17--0.53, *P* = 0.000; *X*^2^ = 1.34, *P* = 0.909, *I*^2^ = 0.0%) (Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Forest plots of the combined HRs with 95%CIs respectively for the (**a**) up-regulated and (**b**) down-regulated circRNA profiles in predicting the overall survival (OS) of patients with CRC Fig. 4Sensitivity analysis of the outlier data for (**a**) the overall diagnostic studies, (**b**) the down-regulated circRNA profiles for diagnosis, as well as (**c**) the up-regulated, and (**d**) down-regulated circRNA expression signature in predicting the OS in CRC

Sensitivity analysis and meta-regression {#Sec14}
----------------------------------------

Results of the sensitivity analysis showed that the effect did not alter when omitting studies one by one in relation to the combined diagnostic effect and prognostic effect of oncogenic circRNAs (Fig. [4](#Fig4){ref-type="fig"}).

To identify the causes of heterogeneity, meta-regression of the pooled diagnostic effect in terms of the specified covariates such as sample size, text matrix, circRNA signature, expression status, reference gene, and quality score was conducted. The results showed that circRNA expression status (pooled DOR = 3.67, 95%CI: 1.10--12.28, *P* = 0.0386), and reference gene (pooled DOR = 0.29, 95%CI: 0.09--0.91, *P* = 0.0383) were likely to be the sources of heterogeneity (detailed data not shown).

Publication bias {#Sec15}
----------------

Deeks' funnel plot asymmetry test showed that no evidence of publication bias (*P* = 0.37) existed for diagnostic analyses (Fig. [5](#Fig5){ref-type="fig"}a and b). Begg's and Egger's tests were also performed to assess publication bias among the eligible articles. There was no obvious publication bias in the prognostic effects according to Begg's test (*P* = 0.129, or 0.266) (Fig. [5](#Fig5){ref-type="fig"}c and d), and Egger's test (detailed data not shown). Therefore, we excluded the possibility of publication bias. Fig. 5Publication bias assessed by the Deek's funnel plot for (**a**) the overall diagnostic effect, and (**b**) the down-regulated circRNA profiles for diagnosis. Begg's test for the (**c**) up-regulated, and (**d**) down-regulated circRNA expression profiling in predicting the OS in CRC

Discussion {#Sec16}
==========

CRC is a major cause of cancer-related deaths worldwide \[[@CR1]--[@CR4]\]. The development of novel diagnostic and prognostic biomarkers to aid the clinical management of CRC is crucial. CircRNAs have been widely recommended as novel diagnostic and prognostic biomarkers in cancers, especially in CRC \[[@CR9]--[@CR21]\]. However, there are no relevant meta-analyses focused on circRNAs expression in CRC. This study systematically analyzed the clinical, diagnostic, and prognostic significance of abnormally expressed circRNAs in CRC.

Studies have suggested a marked relationship between circRNAs expression and CRC \[[@CR9]--[@CR11], [@CR13], [@CR14], [@CR16], [@CR19], [@CR20]\]. In the present study, abnormally expressed circRNAs were found to be associated with tumor diameter, differentiation, lymphatic metastasis, distant metastasis, TNM stage, and depth of invasion, suggesting that dysregulated circRNAs are implicated in the progression of CRC. Significant correlations were not found for age, gender, tumor location, CEA and CA19--9 levels.

The ROC curve is a comprehensive index, which reflects the sensitivity and specificity of continuous variables \[[@CR27], [@CR28]\]. Our summary outcomes revealed a moderate diagnostic efficacy for circRNAs expression in CRC, and diagnostic sensitivity was estimated to be 0.77, and specificity was 0.67. The pooled AUC of circRNAs indicated that 78% of randomly chosen CRC patients would have lower or higher levels of circRNA(s) than normal controls. The pooled DOR is also an important indicator that facilitates formal meta-analysis of studies on diagnostic test performance \[[@CR29], [@CR30]\]. In the present study, a pooled DOR of 7.52 (higher than 1.0) was obtained, suggesting that dysregulation of circRNA expression is a powerful predictive biomarker for CRC diagnosis. As circRNAs with different expression status may exert different functions in CRC, we conducted subgroup analyses. Stratified analysis based on circRNA expression status showed that circRNAs, which function as tumor promoters, yielded higher efficacy than tumor suppressors, and tissue-based circRNA analysis showed higher diagnostic efficacy than plasma-based analysis. However, the sample size was reduced in the subgroup analyses; thus, the accuracy was compromised. Moreover, when taking conserved sequences and stable structures into consideration, circRNAs may serve as novel noninvasive biomarkers in CRC detection.

Studies have documented that circRNAs with dysregulated expression are emerging as independent risk factors for OS in cancer \[[@CR31], [@CR32]\]. Consistent with these data, our pooled effect sizes demonstrated that oncogenic circRNAs overexpression was strongly correlated with decreased OS time in patients with CRC (HR = 2.66, *P* = 0.000). With regard to the prognostic significance of down-regulated circRNAs (may function as tumor suppressors), we identified one outlier study in the combined effects of decreased circRNAs by sensitivity analysis, and the weighted effect showed that decreased circRNAs expression was associated with improved OS in patients with CRC (HR = 0.30, *P* = 0.000).

To identify the cause of study heterogeneity, we first performed sensitivity analysis. The results showed that studies were relatively homogeneous in the overall combined diagnostic effect and prognostic effect of oncogenic circRNAs. However, we identified an outlier study in the pooled prognostic significance of down-regulated circRNAs; thus, the effect size was weighted. On the one hand, the meta-regression test further showed that circRNA expression status and the reference gene were likely to be the sources of heterogeneity. We included 13 types of circRNAs with a different expression status in CRC, and the quantitative analysis was based on different reference genes (*GAPDH, 18S rRNA*, or *U6*); therefore, the heterogeneity was generated in the pooled effects. On the other hand, neither the Deeks' funnel plot asymmetry test nor the Egger test and Begg's funnel plot revealed obvious publication bias for the diagnostic and prognostic meta-analyses, suggesting that all pooled effect sizes were reliable.

Several limitations should be acknowledged in our study. Firstly, although we combined individual studies and increased the number of cases, heterogeneity was observed in some combined effects. Secondly, the small sample size in sub-group analyses as well as the indirectly extracted HR values may increase the insufficiency of statistical power. Finally, population bias may exist in our analyses as most of the studies were conducted in China.

Conclusions {#Sec17}
===========

In summary, the results of the meta-analysis revealed that circRNAs are promising diagnostic and prognostic biomarkers in patients with CRC, and may therefore serve as therapeutic target(s). Further prospective studies on more types of circRNAs are warranted in the future.
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